Overview

Effect Of Rilapladib (SB-659032) On Platelet Aggregation

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline